Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer
The Phase I dose escalation trial of ACESOT-1051 (NCT06260514) will accelerate its patient enrollment, with Aprea planning to more than triple its number of active clinical sites for the study from three to 10. The expansion is expected to accelerate the pace of clinical data generation by raising monthly enrollment to between six and 10 patients by the fourth quarter. The post Aprea Expands…
Aprea Therapeutics is intensifying enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, and expanding its indications after observing early clinical activity signs. The ongoing trial will see patient enrollment more than triple, increasing from three to 10 active sites by the fourth quarter. Aprea aims to generate clinical data monthly, with updated data to be shared at a medical meeting in the fourth quarter.
WEE1 kinase inhibition targets the G2 checkpoint, regulating cell division and ensuring DNA repair. Aprea is also broadening APR-1051's development by advancing it in in uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC), enrolling at least 50 patients in each. The company plans to initiate combination regimens, including HPV-positive head and neck squamous cell carcinoma and colorectal cancer, in ongoing Phase I trials.
Positive early results include a patient with PPP2R1A-mutated endometrial cancer experiencing a 50% reduction in target lesion size and an 87% decline in CA-125 levels after a 220 mg dose.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
